Patents Assigned to Baylor Research Institute
-
Publication number: 20240131138Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.Type: ApplicationFiled: December 22, 2021Publication date: April 25, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Sylvain CARDINAUD, Mireille CENTLIVRE, Lydie DIEUDONNE, Sandra ZURAWSKI, Gérard ZURAWSKI
-
Publication number: 20240124532Abstract: Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors have set up candidate vaccines against Chlamydia trachomatis. In particular, the inventors have identified specific epitopes to be included in vaccine candidates thanks to in silico analysis of the amino-acid sequence of these proteins to map predicted MHC-I and -II epitopes by online software (NetMHC-4.0 and NetMHCII-2.3) and peptide binding prediction software. B cell epitopes were also mapped using online software (BepiPred-2.0 and Discotope). Finally, the inventors have generated some specific CD40 or Langerin antibodies comprising one or more identified epitope(s) of the present invention and that are suitable for vaccine purposes. Therefore, the present invention relates to Chlamydia trachomatis (Ct) antigenic polypeptides and uses thereof for vaccine purposes.Type: ApplicationFiled: January 28, 2022Publication date: April 18, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris, Universite Paris Est Creteil Val De Marne, Baylor Research InstituteInventors: Yves LEVY, Sandra ZURAWSKI, Gérard ZURAWSKI, Mireille CENTLIVRE, Lydie DIEUDONNE, Sylvain CARDINAUD
-
Patent number: 11957734Abstract: Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders.Type: GrantFiled: March 25, 2021Date of Patent: April 16, 2024Assignee: Baylor Research InstituteInventors: SangKon Oh, Sandra Zurawski, Hyemee Joo, Gerard Zurawski
-
Publication number: 20240033340Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.Type: ApplicationFiled: June 6, 2023Publication date: February 1, 2024Applicant: BAYLOR RESEARCH INSTITUTEInventors: SangKon OH, Sandra ZURAWSKI, Gerard ZURAWSKI
-
Publication number: 20240010739Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.Type: ApplicationFiled: November 10, 2021Publication date: January 11, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
-
Patent number: 11806390Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: April 12, 2021Date of Patent: November 7, 2023Assignee: BAYLOR RESEARCH INSTITUTEInventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
-
Patent number: 11717567Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.Type: GrantFiled: March 8, 2021Date of Patent: August 8, 2023Assignee: Baylor Research InstituteInventors: SangKon Oh, Sandra Zurawski, Gerard Zurawski
-
Publication number: 20230212231Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.Type: ApplicationFiled: May 26, 2021Publication date: July 6, 2023Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Baylor Research Institute, Assistance Publique - Hopitaux de Paris (APHP), Universite Paris Est Creteil Val de MarneInventors: Yves LEVY, Gérard ZURAWSKI, Sandra ZURAWSKI, Christine LACABARATZ, Sylvain CARDINAUD, Mathieu SURENAUD
-
Patent number: 11666286Abstract: Computational techniques are applied to video images of polyps to extract features and patterns from different perspectives of a polyp. The extracted features and patterns are synthesized using registration techniques to remove artifacts and noise, thereby generating improved images for the polyp. The generated images of each polyp can be used for training and testing purposes, where a machine learning system separates two types of polyps.Type: GrantFiled: June 30, 2021Date of Patent: June 6, 2023Assignees: BAYLOR RESEARCH INSTITUTE, WRIGHT STATE UNIVERSITYInventors: Themistocles Dassopoulos, Nikolaos Bourbakis
-
Patent number: 11618926Abstract: Dysregulated expression of microRNAs (miRNAs) has emerged as a hallmark feature in human cancers. Aspects of the disclosure relate to methods for selecting optimal therapy for a patient from several alternative treatment options. A major clinical challenge in cancer treatment is to identify the subset of patients who will benefit from a therapeutic regimen, both in metastatic and adjuvant settings. The number of anti-cancer drugs and multi-drug combinations has increased substantially in the past decade, however, treatments continue to be applied empirically using a trial-and-error approach. Here methods and compositions are provided to determine the optimal treatment option for cancer patients.Type: GrantFiled: February 28, 2018Date of Patent: April 4, 2023Assignee: Baylor Research InstituteInventors: Ajay Goel, Raju Kandimalla, Shusuke Toden, Roshni Roy, Tsuyoshi Ozawa, Takatoshi Matsuyama, Wenhao Weng
-
Patent number: 11571365Abstract: This disclosure includes intraluminal tubes comprising: an elongated tube (e.g., having a proximal portion, a distal portion configured to be disposed inside of an internal cavity of a patient, and a sidewall defining a lumen extending from the proximal portion to the distal portion, the distal portion defining one or more openings in fluid communication with the lumen) and a plurality of deployable tines, each coupled to the tube and disposed outside the sidewall of the distal portion, where each tine is movable from a collapsed state to a deployed state in which a portion of the tine extends laterally away from the distal portion of the tube. In some of the present intraluminal tubes, the sidewall of the distal portion defines a plurality of longitudinal grooves, and each tine is disposed in a different one of the grooves when the tines are in the collapsed state.Type: GrantFiled: September 9, 2015Date of Patent: February 7, 2023Assignee: BAYLOR RESEARCH INSTITUTEInventor: Steven G. Leeds
-
Publication number: 20220395482Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.Type: ApplicationFiled: April 22, 2022Publication date: December 15, 2022Applicant: Baylor Research InstituteInventor: Charles R. ROE
-
Patent number: 11406688Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.Type: GrantFiled: July 20, 2020Date of Patent: August 9, 2022Assignee: BAYLOR RESEARCH INSTITUTEInventors: Jacques F. Banchereau, Maria Virginia Pascual
-
Publication number: 20220226448Abstract: Methods and compositions using artificial antigen presenting cells in immunotherapy. The artificial antigen presenting cells comprise substrate particles bound to endogenous MHC-peptide complexes obtained from one or more cells. Methods include administering the artificial antigen presenting cells to a patient to activate antigen-specific T cells.Type: ApplicationFiled: May 22, 2020Publication date: July 21, 2022Applicant: BAYLOR RESEARCH INSTITUTEInventors: Botond Z. IGYÁRTÓ, Qingtai SU
-
Publication number: 20220152192Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.Type: ApplicationFiled: November 9, 2021Publication date: May 19, 2022Applicant: BAYLOR RESEARCH INSTITUTEInventors: SangKon OH, Dapeng LI
-
Patent number: 11267895Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.Type: GrantFiled: June 15, 2020Date of Patent: March 8, 2022Assignee: Baylor Research InstituteInventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
-
Publication number: 20220054609Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.Type: ApplicationFiled: September 14, 2021Publication date: February 24, 2022Applicant: BAYLOR RESEARCH INSTITUTEInventors: SangKon OH, Gerard ZURAWSKI
-
Patent number: 11219683Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).Type: GrantFiled: June 19, 2020Date of Patent: January 11, 2022Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE M{circumflex over (D)}DICALE (INSERM), UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, BAYLOR RESEARCH INSTITUTEInventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
-
Publication number: 20210397904Abstract: Computational techniques are applied to video images of polyps to extract features and patterns from different perspectives of a polyp. The extracted features and patterns are synthesized using registration techniques to remove artifacts and noise, thereby generating improved images for the polyp. The generated images of each polyp can be used for training and testing purposes, where a machine learning system separates two types of polyps.Type: ApplicationFiled: June 30, 2021Publication date: December 23, 2021Applicants: BAYLOR RESEARCH INSTITUTE, WRIGHT STATE UNIVERSITYInventors: Themistocles DASSOPOULOS, Nikolaos BOURBAKIS
-
Patent number: 11173202Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.Type: GrantFiled: April 2, 2019Date of Patent: November 16, 2021Assignee: Baylor Research InstituteInventors: SangKon Oh, Dapeng Li